The future of the global MRD Testing Market looks promising with opportunities in the hospitals and specialty clinic, diagnostic laboratory, and academic & research institutes markets. The global MRD testing market is expected to reach an estimated $4.4 billion by 2030 with a CAGR of 12.8% from 2024 to 2030. The major drivers for this market are increasing occurrence of blood-related cancers, growing global elderly population, and progress in technology for minimal residual disease (MRD) testing.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the MRD testing market by
technology (flow cytometry, polymerase chain reaction (PCR), next-generation
sequencing (NGS), and others), application (hematological malignancies,
leukemia, lymphoma, solid tumors, and others), end use industry (hospitals and
specialty clinics, diagnostic laboratories, academic & research institutes,
and others), and region (North America, Europe, Asia Pacific, and the Rest of
the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, flow
cytometry, polymerase chain reaction (PCR), and next-generation sequencing
(NGS) are the major segments of MRD testing market by technology. Lucintel
forecasts that PCR is expected to witness highest growth over the forecast
period.Within this market, hospitals and specialty clinics will remain the
largest segment.
APAC is expected to
witness highest growth over the forecast period.
Labcorp, F. Hoffmann-La
Roche, Guardant Health, Sysmex Corporation, NeoGenomics Laboratories, Adaptive
Biotechnologies Corporation, ArcherDX, Asuragen, and Arup Laboratories are the
major suppliers in the MRD testing market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
4. Wheelchair Market :
5. 3D
Printing Medical Device Market:
8. Medical Lifting Sling
Market:
10. Stretcher Market:
No comments:
Post a Comment